Last reviewed · How we verify

topiramate, phenytoin — Competitive Intelligence Brief

topiramate, phenytoin (topiramate, phenytoin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant. Area: Neurology.

phase 3 Anticonvulsant Voltage-dependent sodium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

topiramate, phenytoin (topiramate, phenytoin) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Topiramate is an anticonvulsant that works by blocking voltage-dependent sodium channels, stabilizing neuronal membranes, and reducing the release of excitatory neurotransmitters.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
topiramate, phenytoin TARGET topiramate, phenytoin Johnson & Johnson Pharmaceutical Research & Development, L.L.C. phase 3 Anticonvulsant Voltage-dependent sodium channels
Topiramate; Carbamazepine; Valproate Topiramate; Carbamazepine; Valproate Johnson & Johnson Pharmaceutical Research & Development, L.L.C. phase 3 Anticonvulsants Voltage-dependent sodium channels
topiramate, propranolol topiramate, propranolol Johnson & Johnson Pharmaceutical Research & Development, L.L.C. phase 3 Anticonvulsant Voltage-dependent sodium channels, GABA_A receptor
Topiramate (drug) Topiramate (drug) Erasmus Medical Center phase 3 Sulfamate-substituted monosaccharide Voltage-dependent sodium channels, GABA receptors
Neurontin gabapentin Generic (originally Parke-Davis/Pfizer) marketed Gabapentinoid (anticonvulsant/neuropathic pain agent) Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor 1993-12-30
Magnesium Sulfate Magnesium Sulfate Pfizer marketed Electrolyte; anticonvulsant Neuromuscular junction; motor nerve impulse; acetylcholine release 1981-01-01
gabapentin + tramadol gabapentin + tramadol Southwest Hospital, China marketed Analgesic combination (anticonvulsant + opioid) Voltage-gated calcium channels (Cav2.1, Cav2.2); μ-opioid receptor; serotonin and norepinephrine transporters

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant class)

  1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 drugs in this class
  2. Ajou University School of Medicine · 1 drug in this class
  3. CAMC Health System · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hospital Universitari de Bellvitge · 1 drug in this class
  6. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). topiramate, phenytoin — Competitive Intelligence Brief. https://druglandscape.com/ci/topiramate-phenytoin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: